(19)
(11) EP 2 405 269 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.10.2016 Bulletin 2016/41

(45) Mention of the grant of the patent:
24.08.2016 Bulletin 2016/34

(21) Application number: 10748464.4

(22) Date of filing: 23.02.2010
(51) International Patent Classification (IPC): 
G01N 33/574(2006.01)
G01N 37/00(2006.01)
 G01N 21/64(2006.01)
(86) International application number:
PCT/JP2010/001203
(87) International publication number:
WO 2010/100862 (10.09.2010 Gazette 2010/36)

(54)

METHOD FOR DETECTING AND DISTINGUISHING INTRAHEPATIC CHOLANGIOCARCINOMA

VERFAHREN ZUM DETEKTIEREN UND DIFFERENZIEREN INTRAHEPATISCHEN CHOLANGIOKARZINOMS

PROCÉDÉ DE DÉTECTION ET DE DISTINCTION D'UN CHOLANGIOCARCINOME INTRAHÉPATIQUE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 05.03.2009 JP 2009051935

(43) Date of publication of application:
11.01.2012 Bulletin 2012/02

(73) Proprietors:
  • National Institute of Advanced Industrial Science and Technology
    Tokyo 100-8921 (JP)
  • University of Tsukuba
    Tsukuba-shi, Ibaraki 305-8577 (JP)

(72) Inventors:
  • KUNO, Atsushi
    Tsukuba-shi Ibaraki 305-8568 (JP)
  • HIRABAYASHI, Jun
    Tsukuba-shi Ibaraki 305-8568 (JP)
  • MATSUDA, Atsushi
    Tsukuba-shi Ibaraki 305-8568 (JP)
  • NARIMATSU, Hisashi
    Tsukuba-shi Ibaraki 305-8568 (JP)
  • IKEHARA, Yuzuru
    Tsukuba-shi Ibaraki 305-8568 (JP)
  • SHODA, Junichi
    Tsukuba-shi Ibaraki 305-8577 (JP)
  • KAWAMOTO, Toru
    Toride-shi Ibaraki 300-1546 (JP)

(74) Representative: Hamer, Christopher K. et al
Mathys & Squire LLP
The Shard 32 London Bridge Street London SE1 9SG
The Shard 32 London Bridge Street London SE1 9SG (GB)


(56) References cited: : 
EP-A1- 1 380 840
 JP-A- 2003 116 580
   
  • MATSUDA A ET AL: "Development of an all-in-one technology for glycan profiling targeting formalin-embedded tissue sections", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 370, no. 2, 30 May 2008 (2008-05-30), pages 259-263, XP022618888, ACADEMIC PRESS INC. ORLANDO, FL, US ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2008.03.090 [retrieved on 2008-03-28]
  • HIGASHI M ET AL: "Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.", HEPATOLOGY (BALTIMORE, MD.), vol. 30, no. 6, December 1999 (1999-12), pages 1347-1355, XP002678423, ISSN: 0270-9139
  • XU HUANLI ET AL: "Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma", HEPATO-GASTROENTEROLOGY, vol. 55, no. 88, 1 November 2008 (2008-11-01), pages 2000-2004, XP009160472, THIEME, STUTTGART, DE ISSN: 0172-6390
  • BOONLA CHANCHAI ET AL: "MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma", WORLD JOURNAL OF GASTROENTEROLOGY, vol. 11, no. 32, 1 January 2005 (2005-01-01), pages 4939-4946, XP009160475, WJG PRESS, CN ISSN: 1007-9327
  • SASAKI M ET AL: "Characterization of apomucin expression in intrahepatic cholangiocarcinomas and their precursor lesions: an immunohistochemical study.", HEPATOLOGY (BALTIMORE, MD.), vol. 24, no. 5, November 1996 (1996-11), pages 1074-1078, XP002678424, ISSN: 0270-9139
  • ROMANI ANTONELLO A ET AL: "The associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma", BMC CANCER, vol. 6, no. 1, 26 October 2006 (2006-10-26), page 255, XP021023041, BIOMED CENTRAL, LONDON, GB ISSN: 1471-2407, DOI: 10.1186/1471-2407-6-255
  • DONG HUI ET AL: "Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma", ZHONGHUA ZHONGLIU ZAZHI, September 2008 (2008-09), XP002678425, ISSN: 0253-3766 Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pubmed/191 73916 [retrieved on 2012-06-25]
  • ATSUSHI MATSUDA ET AL: "Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma", HEPATOLOGY, vol. 52, no. 1, 1 July 2010 (2010-07-01), pages 174-182, XP055030660, ISSN: 0270-9139, DOI: 10.1002/hep.23654
  • XU H ET AL.: 'Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma' HEPATOGASTROENTEROLOGY vol. 55, no. 88, 2008, pages 2000 - 2004
  • ATSUSHI KUNO ET AL.: 'Focused Differential Glycan Analysis with thePlatform Antibody- assisted Lectin Profiling forGlycan-related Biomarker Verification' MOLECULAR & CELLULAR PROTEOMICS vol. 8, no. 1, 11 August 2008, pages 99 - 108
  • ATSUSHI MATSUDA ET AL.: 'Development of an all-in-one technology for glycan profiling targetingformalin-embedded tissue sections' BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 370, 28 March 2008, pages 259 - 263
  • WICHUDA BAMRUNGPHON ET AL.: 'A new mucin antibody/enzyme-linked lectin-sandwich assayof serum MUC5AC mucin for the diagnosisof cholangiocarcinoma' CANCER LETTERS vol. 247, 2007, pages 301 - 308
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).